Irreversible electroporation (Nanoknife® treatment) in the field of hepatobiliary surgery: Current status and future perspectives.

Published

Journal Article

We aimed to provide an overview of current understanding on the potential use of irreversible electroporation (IRE) in the field of hepatobiliary surgery with a focus on current results in hepatic and pancreatic cancers, its limitations, and its current directions.Through a review of the literature we have gathered the key articles and trials that are shaping our understanding of the current status of IRE and its prospective uses, and organized them in an easily understandable format showcasing the most up to date results.IRE appears to be comparable in effectiveness and postoperative pain to the more established thermal ablation methods, while having the benefit of avoiding their detrimental thermal effects. In liver cancer, IRE was shown to be efficacious with low levels of local recurrences and only minimal complications. In pancreatic cancer it proved to have significant survival benefits but more significant (although rare) complications compared to the ones seen when IRE is used in liver cancer. Current evidence suggests a promising future for IRE, but clinical randomized control trials, and further developments of treatment protocols are required to come to more stable conclusions on the effectiveness and safety of IRE.IRE is proving to be an adequate method for the treatment of tumors of the pancreas and liver in cases where traditional methods are unavailable. It has been proven particularly efficacious in patients with masses in close proximity to vital structures such as vessels, as well as major biliary and hepatic structures where thermal methods of ablation would cause significant complications.

Full Text

Duke Authors

Cited Authors

  • Kourounis, G; Paul Tabet, P; Moris, D; Papalambros, A; Felekouras, E; Georgiades, F; Astras, G; Petrou, A

Published Date

  • January 2017

Published In

Volume / Issue

  • 22 / 1

Start / End Page

  • 141 - 149

PubMed ID

  • 28365947

Pubmed Central ID

  • 28365947

Electronic International Standard Serial Number (EISSN)

  • 2241-6293

International Standard Serial Number (ISSN)

  • 1107-0625

Language

  • eng